Published • loading... • Updated
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
Summary by WellandTribune.ca
4 Articles
4 Articles
WellandTribune.ca+3 Reposted by 3 other sources
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma…
Coverage Details
Total News Sources4
Leaning Left4Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
